We also investigated mutations in the novel genes POLE (7.2% of patients) and POLD1 (2.6% of patients), which have recently been highlighted as key drivers of colorectal carcinogenesis for a minority of CRC patients.16 This evidence concerns the gene POLD1 and colorectal carcinoma.